These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21917454)

  • 1. Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
    Zhang X; Hufnagel H; Hou C; Opas E; McKenney S; Crysler C; O'Neill J; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6042-8. PubMed ID: 21917454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
    Zhang X; Hufnagel H; Markotan T; Lanter J; Cai C; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5577-82. PubMed ID: 21783361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Azetidinyl-1-heteroatom linked cyclohexane antagonists of CCR2: patent evaluation.
    Horuk R; Guilford W
    Expert Opin Ther Pat; 2011 Aug; 21(8):1275-80. PubMed ID: 21554155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
    Cherney RJ; Mo R; Meyer DT; Voss ME; Lo YC; Yang G; Miller PB; Scherle PA; Tebben AJ; Carter PH; Decicco CP
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3418-22. PubMed ID: 19481449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.
    Crawford JJ; Kenny PW; Bowyer J; Cook CR; Finlayson JE; Heyes C; Highton AJ; Hudson JA; Jestel A; Krapp S; Martin S; Macfaul PA; McDermott BP; McGuire TM; Morley AD; Morris JJ; Page KM; Ribeiro LR; Sawney H; Steinbacher S; Smith C; Dossetter AG
    J Med Chem; 2012 Oct; 55(20):8827-37. PubMed ID: 22984809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.
    Cherney RJ; Mo R; Meyer DT; Nelson DJ; Lo YC; Yang G; Scherle PA; Mandlekar S; Wasserman ZR; Jezak H; Solomon KA; Tebben AJ; Carter PH; Decicco CP
    J Med Chem; 2008 Feb; 51(4):721-4. PubMed ID: 18232650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
    Cherney RJ; Mo R; Meyer DT; Pechulis AD; Guaciaro MA; Lo YC; Yang G; Miller PB; Scherle PA; Zhao Q; Cvijic ME; Barrish JC; Decicco CP; Carter PH
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6181-4. PubMed ID: 22939233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
    Cumming JG; Bower JF; Waterson D; Faull A; Poyser PJ; Turner P; McDermott B; Campbell AD; Hudson J; James M; Winter J; Wood C
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3895-9. PubMed ID: 22608963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
    Cherney RJ; Brogan JB; Mo R; Lo YC; Yang G; Miller PB; Scherle PA; Molino BF; Carter PH; Decicco CP
    Bioorg Med Chem Lett; 2009 Feb; 19(3):597-601. PubMed ID: 19131247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists.
    Cherney RJ; Mo R; Meyer DT; Voss ME; Yang MG; Santella JB; Duncia JV; Lo YC; Yang G; Miller PB; Scherle PA; Zhao Q; Mandlekar S; Cvijic ME; Barrish JC; Decicco CP; Carter PH
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2425-30. PubMed ID: 20346664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors.
    An H; Kim NJ; Jung JW; Jang H; Park JW; Suh YG
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6297-300. PubMed ID: 21937231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel CCR2 antagonists: investigation of non-aryl/heteroaryl binding motifs.
    Trujillo JI; Huang W; Hughes RO; Rogier DJ; Turner SR; Devraj R; Morton PA; Xue CB; Chao G; Covington MB; Newton RC; Metcalf B
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1827-31. PubMed ID: 21316220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
    Procopiou PA; Barrett JW; Barton NP; Begg M; Clapham D; Copley RC; Ford AJ; Graves RH; Hall DA; Hancock AP; Hill AP; Hobbs H; Hodgson ST; Jumeaux C; Lacroix YM; Miah AH; Morriss KM; Needham D; Sheriff EB; Slack RJ; Smith CE; Sollis SL; Staton H
    J Med Chem; 2013 Mar; 56(5):1946-60. PubMed ID: 23409871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.
    Cherney RJ; Mo R; Yang MG; Xiao Z; Zhao Q; Mandlekar S; Cvijic ME; Charo IF; Barrish JC; Decicco CP; Carter PH
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1843-5. PubMed ID: 24613378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).
    Batt DG; Petraitis JJ; Houghton GC; Modi DP; Cain GA; Corjay MH; Mousa SA; Bouchard PJ; Forsythe MS; Harlow PP; Barbera FA; Spitz SM; Wexler RR; Jadhav PK
    J Med Chem; 2000 Jan; 43(1):41-58. PubMed ID: 10633037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation.
    Procopiou PA; Ford AJ; Graves RH; Hall DA; Hodgson ST; Lacroix YM; Needham D; Slack RJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2730-3. PubMed ID: 22437117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
    Down K; Amour A; Baldwin IR; Cooper AW; Deakin AM; Felton LM; Guntrip SB; Hardy C; Harrison ZA; Jones KL; Jones P; Keeling SE; Le J; Livia S; Lucas F; Lunniss CJ; Parr NJ; Robinson E; Rowland P; Smith S; Thomas DA; Vitulli G; Washio Y; Hamblin JN
    J Med Chem; 2015 Sep; 58(18):7381-99. PubMed ID: 26301626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
    McBride CM; Renhowe PA; Heise C; Jansen JM; Lapointe G; Ma S; Piñeda R; Vora J; Wiesmann M; Shafer CM
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3595-9. PubMed ID: 16603352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
    Pfefferkorn JA; Tu M; Filipski KJ; Guzman-Perez A; Bian J; Aspnes GE; Sammons MF; Song W; Li JC; Jones CS; Patel L; Rasmusson T; Zeng D; Karki K; Hamilton M; Hank R; Atkinson K; Litchfield J; Aiello R; Baker L; Barucci N; Bourassa P; Bourbonais F; D'Aquila T; Derksen DR; MacDougall M; Robertson A
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7100-5. PubMed ID: 23089526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.
    Kothandaraman S; Donnely KL; Butora G; Jiao R; Pasternak A; Morriello GJ; Goble SD; Zhou C; Mills SG; Maccoss M; Vicario PP; Ayala JM; Demartino JA; Struthers M; Cascieri MA; Yang L
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1830-4. PubMed ID: 19237282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.